PharmaCyte Biotech, Inc. (PMCB) Stock Price & Analysis
PharmaCyte Biotech, Inc. (PMCB) closed at USD 0.36 on Thursday, October 15, 2026, up 2.11% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.35; the Oct 15, 2026 session ranged USD 0.34–0.36 on volume of 54,058 shares. Market capitalization is $3.84M, with a 52-week range of USD 0.33–1.51 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:10 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PMCB.md
Key facts (PMCB)
- Last four reported quarters (through Jul 31, 2026): revenue $0K, net income -$16.1M (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -63.3% vs S&P 500 +18.1%; 5Y -88.2% vs S&P 500 +85.1%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PMCB)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $0K | $0K | $0K | $0K |
| Operating income | -$4.4M | -$6.5M | -$8.5M | -$4.4M | -$6.9M | -$7.0M |
| Net income | -$4.2M | -$4.3M | $334K | $30.7M | -$19.4M | -$16.1M |
| EPS (diluted) | -$0.27 | -$0.22 | -$1.80 | $3.19 | -$2.77 | — |
| Cash + short-term investments | $85.4M | $68.0M | $50.2M | $15.5M | $18.9M | — |
Fiscal years end Apr. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 31, 2026) (PMCB)
P/B 0.1x · Earnings yield -420.80%
P/E at fiscal year-ends: Apr 2025 0.3x, Apr 2024 60.9x.
Analysts (PMCB)
Consensus None.
Total return (dividends reinvested) (PMCB)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -63.3% | -88.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -63.5% | -34.8% |
| Volatility (annualized) | 91.4% | 49.9% |
| Max drawdown | -71.4% (Dec 2025→Oct 2026) | -88.7% (May 2023→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:10 UTC)
| Price | USD 0.36 |
|---|---|
| Change | ▲ 2.11% (up) |
| Previous Close | USD 0.35 |
| Open | USD 0.34 |
| Day Range | USD 0.34 – 0.36 |
| 52-Week Range | USD 0.33 – 1.51 |
| Volume | 54,058 shares |
| Market Cap | $3.84M |
| Exchange | NCM |
Technical Analysis (PMCB)
Nexqual's technical model rates PMCB "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.93 (neutral) |
| vs SMA50 | Below (USD 0.47) |
| MACD | -0.03 (negative) |
Analyst Ratings (PMCB)
Wall Street analysts rate PMCB "None", per Nexqual as of October 16, 2026 at 05:10 UTC.
| Consensus Rating | None |
|---|
Earnings (PMCB)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2022-07-31 | USD -0.07 vs est -0.07 ▲ beat |
| 2022-04-30 | USD -0.06 vs est -0.04 ▼ miss |
| 2022-01-31 | USD -0.04 vs est -0.05 ▲ beat |
| 2021-10-31 | USD -0.06 vs est -0.07 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financials & Fundamentals (PMCB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -43.99% |
| Current Ratio | 40.3 |
| Total Cash | $30.51M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financial Health Score (PMCB)
Nexqual rates PharmaCyte Biotech, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $31M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M (FY ended Apr 2026, 10-K) |
| Efficiency | Critical — ROE -44%, ROA -8.3% |
Ownership (PMCB)
| Insider Ownership | +5.74% |
|---|---|
| Institutional Ownership | +7.11% |
| Shares Outstanding | 10.74M |
| Float | 10.07M |
| Short % of Float | +1.32% |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Leadership (PMCB)
PharmaCyte Biotech, Inc. is led by Joshua N. Silverman (age 55), CEO. President & Executive Chairman, per Nexqual as of October 16, 2026 at 05:10 UTC.
| CEO. President & Executive Chairman | Joshua N. Silverman (age 55) |
|---|---|
| Chief Financial Officer | Carlos A. Trujillo (age 67) |
From PharmaCyte Biotech, Inc.'s Latest SEC 10-K Filing (filed 2026-07-29)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, as a condition of approval of an NDA or BLA, the FDA may require post-marketing testing, including a Phase 4 clinical trial and surveillance to further assess and monitor the product's safety and effectiveness after commercialization has begun.
Partnerships
- This group provides authorization for whether a trial may move forward at designated checkpoints based on access that only the group maintains to available data from the study.   A sponsor may be able to request a special protocol assessment ("SPA"), the purpose of which is to reach agreement with the FDA on the Phase 3 trial protocol design, clinical endpoints and statistical analysis that will form the primary basis of an efficacy claim.
- The agreement will be binding on the FDA and may not be changed by the sponsor or the FDA after the trial begins, except with the written agreement of the sponsor and the FDA or if the FDA determines that a substantial scientific issue essential to determining the safety or efficacy of the product candidate was identified after the testing began.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:10 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt